Precision NeuroMed

Precision NeuroMed is a clinical-stage biotechnology company dedicated to developing integrated technologies that target the underlying causes of brain diseases by bypassing the blood-brain barrier. The company's core platform combines convection-enhanced delivery (CED) hardware, AI-driven image-based treatment-planning software, and targeted therapeutics to deliver high local drug concentrations directly to the brain. Its lead investigational candidate, PNM-201 (cintredekin besudotox), is a receptor-targeted cytotoxic fusion protein designed to treat glioblastoma multiforme by targeting the IL-13 alpha-2 receptor. Beyond oncology, Precision NeuroMed is advancing programs for epilepsy, stroke, and neurodegenerative disorders such as Parkinson's and Alzheimer's diseases. The company's approach aims to transform CNS treatment by optimizing drug distribution and improving patient survival and quality of life.